Swedish Orphan Biovitrum Investor Relations Material
Latest events
Q2 2025
Swedish Orphan Biovitrum
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Swedish Orphan Biovitrum
Access all reports
Swedish Orphan Biovitrum AB, an integrated biotechnology company, researches, develops, manufactures, and sells pharmaceuticals in the therapeutic areas of haematology, immunology, and genetic and metabolic diseases in Europe, North America, and internationally. The company operates through three segments: Haemophilia & Hereditary Diseases, Inflammation & Immunology, and Other. It offers Alprolix for hemophilia B; Elocta to treat hemophilia A; Doptelet for thrombocytopenia; Kineret for rheumatoid arthritis; Thiola for cystinuria; Xultophy Cartridge that is used with Flexpen for treatment of diabetes; and Velphoro for hyperphosphatemia.
Key slides for Swedish Orphan Biovitrum
Q1 2025
Swedish Orphan Biovitrum
Q2 2025
Swedish Orphan Biovitrum
Latest articles
)
Stephen J. Squeri: American Express Veteran Chairman and CEO
Stephen Squeri has spent over four decades at American Express, rising through the ranks to lead one of the world's most recognized brands.
15 Sep 2025
)
Where to? The Story of Uber
Uber's journey from rule-breaking disruptor to disciplined dual-app giant, now shaping the future of mobility, delivery, and autonomy.
5 Sep 2025
)
The Dilemma That Brought Down Kodak
Kodak helped invent digital photography but failed to embrace it. How the innovator's dilemma turned an icon into its own most famous casualty.
21 Aug 2025
Ticker symbol
SOBI
Country
🇸🇪 Sweden